Spots Global Cancer Trial Database for FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer
Official Title: Randomized, Double-Blind, Phase II Study of FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment for Patients With Metastatic Colorectal Cancer
Study ID: NCT01418222
Conditions
Study Description
Brief Summary: This randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of FOLFOX/bevacizumab with onartuzumab (MetMAb) versus placebo as first-line treatment in patients with metastatic colorectal cancer.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Almac Clinical Technologies, San Francisco, California, United States
Rocky Mountain Cancer Centers; Bone and Marrow Trans, Denver, Colorado, United States
Florida Cancer Specialists; SCRI, Fort Myers, Florida, United States
Florida Hospital Cancer Inst, Orlando, Florida, United States
Georgia Cancer Specialists - Northside, Atlanta, Georgia, United States
University of Chicago; Hematology/Oncology, Chicago, Illinois, United States
Ingalls Cancer Research Center, Harvey, Illinois, United States
Ingalls Memorial Hospital; Cancer Research Center, Harvey, Illinois, United States
Baptist Hospital East, Louisville, Kentucky, United States
Center For Cancer and Blood Disorders, Bethesda, Maryland, United States
Saint Louis Cancer Care, LLP, Bridgeton, Missouri, United States
Research Medical Center - Antibiotic Research Associates, Inc., Kansas City, Missouri, United States
Hem-Onc Assoc of Northern NJ, Morristown, New Jersey, United States
Oncology Hematology Care Inc, Cincinnati, Ohio, United States
Toledo Comm. Onc. Program, Toledo, Ohio, United States
University of Oklahoma; Stephenson Oklahoma Canc Ctr, Oklahoma City, Oklahoma, United States
South Carolina Oncology Associates - SCRI, Columbia, South Carolina, United States
Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States
SCRI Tennessee Oncology Chattanooga, Chattanooga, Tennessee, United States
Tennessee Onc., PLLC - SCRI, Nashville, Tennessee, United States
Ctr for Cancer and Blood Disorders, Fort Worth, Texas, United States
South Texas Oncology & Hematology, P.A., San Antonio, Texas, United States
Virginia Cancer Institute, Richmond, Virginia, United States
Contact Details
Name: Clinical Trials
Affiliation: Genentech, Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
